Innovent Biologics partnered with Spero Therapeutics Inc. to advance the development of IBI355.
2 reports, 1 independent
Updated Jul 14
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Innovent Biologics partnered with Spero Therapeutics Inc. to advance the development of IBI355.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- HCRx buys into Utebzi milestones and royalties, GSK grants exclusive license for Utebzi, and Spero in-licenses SP001 from Innovent Biologics.Sub-event
Innovent Biologics announced a new partnership with Spero Therapeutics for IBI355 development.1 source
Keep exploring
The entities involved
-
Innovent Biologics
Chinese Biopharmaceutical Company
Nothing else this week.